{"protocolSection": {"identificationModule": {"nctId": "NCT01911780", "orgStudyIdInfo": {"id": "1348.2"}, "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine", "officialTitle": "An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Hydrochlorothiazide 12.5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Hydrochlorothiazide 12.5 mg, Followed by a 52 Weeks Extension Study to Assess Long Term Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg"}, "statusModule": {"statusVerifiedDate": "2016-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-07"}, "primaryCompletionDateStruct": {"date": "2015-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-07-26", "studyFirstSubmitQcDate": "2013-07-26", "studyFirstPostDateStruct": {"date": "2013-07-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-01-22", "resultsFirstSubmitQcDate": "2016-02-26", "resultsFirstPostDateStruct": {"date": "2016-03-28", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2014-06-25", "dispFirstSubmitQcDate": "2014-06-25", "dispFirstPostDateStruct": {"date": "2014-06-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-02-26", "lastUpdatePostDateStruct": {"date": "2016-03-28", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This is a multi-centre, randomised, double-blind, active-controlled, parallel-group comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg + hydrochlorothiazide 12.5 mg and amlodipine 5 mg (T80/A5/H12.5 mg) to telmisartan 80 mg+ hydrochlorothiazide 12.5 mg (T80/H12.5 mg) in blood pressure lowering effect at week 8, the end of the double-blind period in essential hypertensive patients who fail to respond adequately to telmisartan 80 mg+ hydrochlorothiazide 12.5 mg.\n\nPatients are assigned to one of the two groups after a 6-week open-label run-in period taking T80/H12.5 mg.\n\nIn addition the long-term safety of telmisartan 80 mg+ amlodipine 5 mg+ hydrochlorothiazide 12.5 mg will be evaluated in a 52-week extension period.\n\nIn the 52-week open label extension period patients who are assigned to the T80/A5/H12.5 mg group continue the T80/A5/H12.5 mg therapy, and patients who are assigned to the T80/ /H12.5 mg group change to the T80/A5/H12.5 mg therapy."}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE"}}, "enrollmentInfo": {"count": 132, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "telmisartan + HCTZ + amlodipine", "type": "EXPERIMENTAL", "description": "telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)", "interventionNames": ["Drug: telmisartan + HCTZ", "Drug: amlodipine"]}, {"label": "telmisartan + HCTZ + placebo", "type": "ACTIVE_COMPARATOR", "description": "telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)", "interventionNames": ["Drug: placebo", "Drug: telmisartan + HCTZ"]}], "interventions": [{"type": "DRUG", "name": "placebo", "description": "placebo matching amlodipine capsule", "armGroupLabels": ["telmisartan + HCTZ + placebo"]}, {"type": "DRUG", "name": "telmisartan + HCTZ", "description": "FDC tablet", "armGroupLabels": ["telmisartan + HCTZ + placebo"]}, {"type": "DRUG", "name": "telmisartan + HCTZ", "description": "FDC tablet", "armGroupLabels": ["telmisartan + HCTZ + amlodipine"]}, {"type": "DRUG", "name": "amlodipine", "description": "capsule", "armGroupLabels": ["telmisartan + HCTZ + amlodipine"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.", "description": "Change from baseline in mean seated diastolic blood pressure (DBP) at trough (24-hour post dosing) after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.", "timeFrame": "baseline and 8 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.", "description": "Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.", "timeFrame": "baseline and 8 weeks"}, {"measure": "The Percentage of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 8 Weeks of Double-blind Period.", "description": "The percentage of patients with DBP\\<90 mmHg and SBP\\<140 mmHg as seated blood pressure at trough after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.", "timeFrame": "Double-blind and 8 weeks"}, {"measure": "The Number of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 52 Weeks of Extension Period.", "description": "The number of patients with DBP\\<90 mmHg and SBP\\<140 mmHg as seated blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline.\n\nThe results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.", "timeFrame": "Reference baseline (week 0) and week 60 (end of extension period)"}, {"measure": "Change From Baseline in Mean DBP Pressure at Trough After 52 Weeks of the Extension Period.", "description": "Change from baseline in mean seated diastolic blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline.\n\nThe results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.", "timeFrame": "Reference baseline (week 0) and week 60 (end of extension period)"}, {"measure": "Change From Baseline in Mean Seated SBP at Trough After 52 Weeks of the Extension Period.", "description": "Change from baseline in mean seated systolic blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline.\n\nThe results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.", "timeFrame": "Reference baseline (week 0) and week 60 (end of extension period)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n1. Essential hypertensive patients who have already taking 2 or 3 antihypertensive drugs and mean seated diastolic blood pressure (DBP) must be \\>=90 and \\<=114 mmHg and mean seated systolic blood pressure (SBP) must be =\\<200 mmHg\n2. Able to stop all current antihypertensive drugs (other than study medication) from Visit 1b through the end of the trial without risk to the patient based on the investigator's opinion\n3. Age 20 years or older\n\nExclusion criteria:\n\n1. Patients with known or suspected secondary hypertension\n2. Patients with clinically relevant cardiac arrhythmia\n3. Congestive heart failure with New York Heart Association (NYHA) functional class III-IV\n4. Patients with recent cardiovascular events\n5. Patients with recent stroke events\n6. Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers or angiotensin converting enzyme inhibitors; or patients with post-renal transplant or post-nephrectomy\n7. Patients with hepatic and/or renal dysfunction\n8. Pre-menopausal women who are nursing or pregnant", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "maximumAge": "100 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "1348.2.020 Boehringer Ingelheim Investigational Site", "city": "Chiyoda-ku, Tokyo", "country": "Japan"}, {"facility": "1348.2.008 Boehringer Ingelheim Investigational Site", "city": "Chuo-ku, Fukuoka, Fukuoka", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "1348.2.018 Boehringer Ingelheim Investigational Site", "city": "Chuo-ku,Kobe, Hyogo", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "1348.2.006 Boehringer Ingelheim Investigational Site", "city": "Chuo-ku,Tokyo", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "1348.2.013 Boehringer Ingelheim Investigational Site", "city": "Chuo-ku,Tokyo", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "1348.2.021 Boehringer Ingelheim Investigational Site", "city": "Chuo-ku,Tokyo", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "1348.2.012 Boehringer Ingelheim Investigational Site", "city": "Hirakata, Osaka", "country": "Japan"}, {"facility": "1348.2.011 Boehringer Ingelheim Investigational Site", "city": "Kasaoka, Okayama", "country": "Japan"}, {"facility": "1348.2.001 Boehringer Ingelheim Investigational Site", "city": "Kawasaki, Kanagawa", "country": "Japan"}, {"facility": "1348.2.019 Boehringer Ingelheim Investigational Site", "city": "Kita-ku, Osaka-shi, Osaka", "country": "Japan"}, {"facility": "1348.2.014 Boehringer Ingelheim Investigational Site", "city": "Kiyota-ku, Sapporo-shi, Hokkaido", "country": "Japan"}, {"facility": "1348.2.002 Boehringer Ingelheim Investigational Site", "city": "Kumamoto, Kumamoto", "country": "Japan", "geoPoint": {"lat": 32.80589, "lon": 130.69182}}, {"facility": "1348.2.007 Boehringer Ingelheim Investigational Site", "city": "Nakano-ku,Tokyo", "country": "Japan"}, {"facility": "1348.2.009 Boehringer Ingelheim Investigational Site", "city": "Nishi-ku, Fukuoka, Fukuoka", "country": "Japan"}, {"facility": "1348.2.005 Boehringer Ingelheim Investigational Site", "city": "Takatsuki, Osaka", "country": "Japan"}, {"facility": "1348.2.016 Boehringer Ingelheim Investigational Site", "city": "Uji, Kyoto", "country": "Japan"}, {"facility": "1348.2.010 Boehringer Ingelheim Investigational Site", "city": "Yoshikawa, Saitama", "country": "Japan"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "An eight-week randomised, double-blind study with active-control and parallel-group comparison in Japanese patients plus 52 week extension period.", "recruitmentDetails": "Of the 239 enrolled patients, 205 patients were entered in the run-in period and 132 were randomized. The remaining 107 patients were withdrawn from the trial before the randomization.", "groups": [{"id": "FG000", "title": "Telmisartan + HCTZ + Amlodipine", "description": "telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule orally, once daily (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)"}, {"id": "FG001", "title": "Telmisartan + HCTZ + Placebo", "description": "telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule orally, once daily (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)"}], "periods": [{"title": "Double-blind Period (8 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "68"}, {"groupId": "FG001", "numSubjects": "64"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "65"}, {"groupId": "FG001", "numSubjects": "61"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Consent withdrawn not due to AEs", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Personal reason", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Extension Period (52 Weeks)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "65"}, {"groupId": "FG001", "numSubjects": "61"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "61"}, {"groupId": "FG001", "numSubjects": "58"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Consent withdrawn not due to AEs", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Personal reason", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Treated set (TS) was defined as a collection of patients i) randomised to the double-blind period; ii) taking at least 1 dose of either T80/A5/H12.5 mg or T80/H12.5 mg during the double-blind period.", "groups": [{"id": "BG000", "title": "Telmisartan + HCTZ + Amlodipine", "description": "telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule orally, once daily (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)"}, {"id": "BG001", "title": "Telmisartan + HCTZ + Placebo", "description": "telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule orally, once daily (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "68"}, {"groupId": "BG001", "value": "64"}, {"groupId": "BG002", "value": "132"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.1", "spread": "10.2"}, {"groupId": "BG001", "value": "54.4", "spread": "7.9"}, {"groupId": "BG002", "value": "55.2", "spread": "9.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "28"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "49"}, {"groupId": "BG002", "value": "104"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.", "description": "Change from baseline in mean seated diastolic blood pressure (DBP) at trough (24-hour post dosing) after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.", "populationDescription": "Full analysis set (FAS) was, conforming to the intent-to-treat principle, defined as all patients i) included in the treated set; and ii) taking measurements of seated DBP at reference baseline and at 1 or more time points during the double-blind period", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "baseline and 8 weeks", "groups": [{"id": "OG000", "title": "Telmisartan + HCTZ + Amlodipine", "description": "telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule orally, once daily (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)"}, {"id": "OG001", "title": "Telmisartan + HCTZ + Placebo", "description": "telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule orally, once daily (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "64"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-8.8", "spread": "0.8"}, {"groupId": "OG001", "value": "-1.3", "spread": "0.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "LOCF-ANCOVA", "statisticalComment": "Last observation carried forward (LOCF) was used as the imputation method", "paramType": "Adjusted mean, comparison", "paramValue": "-7.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.7", "ciUpperLimit": "-5.3", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.1", "estimateComment": "Model includes baseline DBP as a linear covariate, and treatment and center as fixed effects."}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.", "description": "Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "baseline and 8 weeks", "groups": [{"id": "OG000", "title": "Telmisartan + HCTZ + Amlodipine", "description": "telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule orally, once daily (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)"}, {"id": "OG001", "title": "Telmisartan + HCTZ + Placebo", "description": "telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule orally, once daily (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "64"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.6", "spread": "1.4"}, {"groupId": "OG001", "value": "-2.1", "spread": "1.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Additional information, the p-value is not adjusted for multiplicity.", "statisticalMethod": "LOCF-ANCOVA", "paramType": "Adjusted mean, comparison", "paramValue": "-8.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.7", "ciUpperLimit": "-4.5", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "2.1", "estimateComment": "Model includes baseline SBP as a linear covariate, and treatment and center as fixed effects."}]}, {"type": "SECONDARY", "title": "The Percentage of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 8 Weeks of Double-blind Period.", "description": "The percentage of patients with DBP\\<90 mmHg and SBP\\<140 mmHg as seated blood pressure at trough after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Participants", "timeFrame": "Double-blind and 8 weeks", "groups": [{"id": "OG000", "title": "Telmisartan + HCTZ + Amlodipine", "description": "telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule orally, once daily (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)"}, {"id": "OG001", "title": "Telmisartan + HCTZ + Placebo", "description": "telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule orally, once daily (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "64"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "44.8", "lowerLimit": "32.6", "upperLimit": "57.4"}, {"groupId": "OG001", "value": "21.9", "lowerLimit": "12.5", "upperLimit": "34.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0052", "pValueComment": "Additional information, the p-value is not adjusted for multiplicity.", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Non-completers considered failures (NCF) was used as the imputation method.", "paramType": "Odds Ratio (OR)", "paramValue": "3.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.4", "ciUpperLimit": "7.1", "estimateComment": "Exact 95 % confidence interval by Clopper and Pearson. Logistic regression includes treatment and center."}]}, {"type": "SECONDARY", "title": "The Number of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 52 Weeks of Extension Period.", "description": "The number of patients with DBP\\<90 mmHg and SBP\\<140 mmHg as seated blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline.\n\nThe results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.", "populationDescription": "FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Reference baseline (week 0) and week 60 (end of extension period)", "groups": [{"id": "OG000", "title": "Telmisartan + HCTZ + Amlodipine", "description": "telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule orally, once daily (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)"}, {"id": "OG001", "title": "Telmisartan + HCTZ + Placebo", "description": "telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule orally, once daily (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "61"}]}], "classes": [{"title": "Yes", "categories": [{"measurements": [{"groupId": "OG000", "value": "41", "lowerLimit": "32.6", "upperLimit": "57.4"}, {"groupId": "OG001", "value": "33", "lowerLimit": "12.5", "upperLimit": "34.0"}]}]}, {"title": "No", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "28"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean DBP Pressure at Trough After 52 Weeks of the Extension Period.", "description": "Change from baseline in mean seated diastolic blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline.\n\nThe results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.", "populationDescription": "FAS in the extension period (FASEX OC) was defined as a collection of patients i) included in the FAS; ii) taking at least 1 dose of T80/A5/H12.5 mg in the extension period; and iii) taking measurements of seated DBP at reference baseline and at 1 or more time points in the extension period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Reference baseline (week 0) and week 60 (end of extension period)", "groups": [{"id": "OG000", "title": "Telmisartan + HCTZ + Amlodipine + Ext", "description": "telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule orally, once daily (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)"}, {"id": "OG001", "title": "Telmisartan + HCTZ + Placebo + Ext", "description": "telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule orally, once daily (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "58"}]}], "classes": [{"title": "Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.4", "spread": "1.0"}, {"groupId": "OG001", "value": "-10.0", "spread": "1.0"}]}]}, {"title": "Adjusted mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.9", "spread": "1.0"}, {"groupId": "OG001", "value": "-10.5", "spread": "1.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "mixed-effects model repeated measures", "paramType": "Adjusted Mean", "paramValue": "-0.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.1", "ciUpperLimit": "2.3", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.4", "estimateComment": "As a linear covariate, and treatment and visit, treatment by visit interaction and baseline value by visit interaction as fixed effects."}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Seated SBP at Trough After 52 Weeks of the Extension Period.", "description": "Change from baseline in mean seated systolic blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline.\n\nThe results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.", "populationDescription": "FASEX (OC)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Reference baseline (week 0) and week 60 (end of extension period)", "groups": [{"id": "OG000", "title": "Telmisartan + HCTZ + Amlodipine + Ext", "description": "telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule orally, once daily (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)"}, {"id": "OG001", "title": "Telmisartan + HCTZ + Placebo + Ext", "description": "telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule orally, once daily (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "58"}]}], "classes": [{"title": "Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.8", "spread": "1.6"}, {"groupId": "OG001", "value": "-14.3", "spread": "1.6"}]}]}, {"title": "Adjusted mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.6", "spread": "1.3"}, {"groupId": "OG001", "value": "-15.9", "spread": "1.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "statisticalMethod": "mixed-effects model repeated measures", "paramType": "Adjusted Mean", "paramValue": "2.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.5", "ciUpperLimit": "6.1", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "1.9", "estimateComment": "Model includes baseline SBP as a linear covariate, and treatment and visit, treatment by visit interaction and baseline value by visit interaction as fixed effects."}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 60 weeks", "eventGroups": [{"id": "EG000", "title": "Telmisartan + HCTZ + Amlodipine - Double Blind Period", "description": "Telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule orally, once daily for 8 weeks (double blind period)", "seriousNumAffected": 0, "seriousNumAtRisk": 68, "otherNumAffected": 7, "otherNumAtRisk": 68}, {"id": "EG001", "title": "Telmisartan + HCTZ + Placebo - Double Blind Period", "description": "Telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule orally, once daily for 8 weeks (double-blind period)", "seriousNumAffected": 0, "seriousNumAtRisk": 64, "otherNumAffected": 6, "otherNumAtRisk": 64}, {"id": "EG002", "title": "Telmisartan + HCTZ + Amlodipine - Extension Period", "description": "Patients in the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet who previously received telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule orally, once daily for 8 weeks in the double blind period. Adverse events which occurred in extension period were collected.", "seriousNumAffected": 2, "seriousNumAtRisk": 65, "otherNumAffected": 26, "otherNumAtRisk": 65}, {"id": "EG003", "title": "Telmisartan + HCTZ + Placebo - Extension Period", "description": "Patients in the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet who previously received telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule orally, once daily for 8 weeks in the double-blind period. Adverse events which occurred in extension period were collected.", "seriousNumAffected": 2, "seriousNumAtRisk": 61, "otherNumAffected": 16, "otherNumAtRisk": 61}], "seriousEvents": [{"term": "Large intestine polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 64}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 61}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 64}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 61}]}, {"term": "Spinal fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 64}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 61}]}, {"term": "Lacunar infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 64}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 65}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 61}]}, {"term": "Haemothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 64}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 61}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 64}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 61}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 64}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 65}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 61}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 64}, {"groupId": "EG002", "numAffected": 23, "numAtRisk": 65}, {"groupId": "EG003", "numAffected": 16, "numAtRisk": 61}]}, {"term": "Upper respiratory tract inflammation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 68}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 64}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 65}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 61}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights."}, "pointOfContact": {"title": "Boehringer Ingelheim, Call Center", "organization": "Boehringer Ingelheim", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000077333", "term": "Telmisartan"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M1770", "name": "Telmisartan", "asFound": "Fixed dose", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "CRC", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}